Phenotypic profiling of raf inhibitors and mitochondrial toxicity in 3D tissue using biodynamic imaging

Journal of Biomolecular Screening

Volumn 19, Issue 4, 2014, Pages 526-537

  An, Ran ^a   Merrill, Dan ^a   Avramova, Larisa ^a   Sturgis, Jennifer ^a   Tsiper, Maria ^b   Robinson, J Paul ^a   Turek, John ^a   Nolte, David D ^a  

^a PURDUE UNIVERSITY   (United States)

^b PolyomicSolutions LLC   (United States)

Author keywords

cell based assays; imaging technologies; label free technologies; phenotypic drug discovery

Indexed keywords

B RAF KINASE INHIBITOR; IONOMYCIN; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NICARDIPINE; SORAFENIB; VALINOMYCIN; VEMURAFENIB;

ARTICLE; BIODYNAMIC IMAGING; CANCER CELL CULTURE; CELL CULTURE; COLON ADENOCARCINOMA; CONTENT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMAGING SYSTEM; MITOCHONDRIAL TOXICITY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SPECTROSCOPY; THREE DIMENSIONAL IMAGING; TISSUE DYNAMICS SPECTROSCOPY; TUMOR SPHEROID;

CELL-BASED ASSAYS; IMAGING TECHNOLOGIES; LABEL-FREE TECHNOLOGIES; PHENOTYPIC DRUG DISCOVERY;

CELL LINE, TUMOR; CLUSTER ANALYSIS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MITOCHONDRIA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SPECTROPHOTOMETRY; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84896741524     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113516674     Document Type: Article

References (35)

1. Swinney D. C., Anthony J.. How Were New Medicines Discovered?. Nat. Rev. Drug Discov. 2011 ; 10: 507-519
2. Feng Y., Mitchison T. J., Bender A., et al. Multi-parameter Phenotypic Profiling: Using Cellular Effects to Characterize Small-Molecule Compounds. Nat. Rev. Drug Discov. 2009 ; 8: 567-578
3. Lee J. A., Uhlik M. T., Moxham C. M., et al. Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy. J. Med. Chem. 2012 ; 55: 4527-4538
4. Swinney D. C.. Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines. Clin. Pharmacol. Ther. 2013 ; 93: 299-301
5. Caie P. D., Walls R. E., Ingleston-Orme A., et al. High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells. Mol. Cancer Ther. 2010 ; 9: 1913-1926
6. Perlman Z. E., Slack M. D., Feng Y., et al. Multidimensional Drug Profiling by Automated Microscopy. Science. 2004 ; 306: 1194-1198 (Pubitemid 39489001)
7. Bullen A.. Microscopic Imaging Techniques for Drug Discovery. Nat. Rev. Drug Discov. 2008 ; 7: 54-67
8. Pampaloni F., Reynaud E. G., Stelzer E. H. K.. The Third Dimension Bridges the Gap between Cell Culture and Live Tissue. Nat. Rev. Mol. Cell Biol. 2007 ; 8: 839-845 (Pubitemid 47462131)
9. Gaedtke L., Thoenes L., Culmsee C., et al. Proteomic Analysis Reveals Differences in protein Expression in Spheroid versus Monolayer Cultures of Low-Passage Colon Carcinoma Cells. J. Proteome Res. 2007 ; 6: 4111-4118 (Pubitemid 350158489)
10. Chang T. T., Hughes-Fulford M.. Monolayer and Spheroid Culture of Human Liver Hepatocellular Carcinoma Cell Line Cells Demonstrate Distinct Global Gene Expression Patterns and Functional Phenotypes. Tissue Eng. A. 2009 ; 15: 559-567
11. Hazlehurst L. A., Landowski T. H., Dalton W. S.. Role of the Tumor Microenvironment in Mediating De Novo Resistance to Drugs and Physiological Mediators of Cell Death. Oncogene. 2003 ; 22: 7396-7402 (Pubitemid 37487165)
12. Jeong K., Turek J. J., Nolte D. D.. Fourier-Domain Digital Holographic Optical Coherence Imaging of Living Tissue. Appl. Opt. 2007 ; 46: 4999-5008 (Pubitemid 47632056)
13. Yu P., Peng L., Mustata M., et al. Time-Dependent Speckle in Holographic Optical Coherence Imaging and the State of Health of Tumor Tissue. Optics Lett. 2004 ; 29: 68-70
14. Jeong K., Turek J. J., Nolte D. D.. Imaging Motility Contrast in Digital Holography of Tissue Response to Cytoskeletal Anti-Cancer Drugs. Optics Express. 2007 ; 15: 14057-14064 (Pubitemid 47608615)
15. Bizheva K. K., Siegel A. M., Boas D. A.. Path-Length-Resolved Dynamic Light Scattering in Highly Scattering Random Media: The Transition to Diffusing Wave Spectroscopy. Phys. Rev. E. 1998 ; 58: 7664-7667 (Pubitemid 128593276)
16. Wax A., Yang C. H., Dasari R. R., et al. Path-Length-Resolved Dynamic Light Scattering: Modeling the Transition from Single to Diffusive Scattering. Appl. Optics. 2001 ; 40: 4222-4227
17. An R., Turek J., Matei D. E., et al. Live Tissue Viability and Chemosensitivity Assays Using Digital Holographic Motility Contrast Imaging. Appl. Optics. 2013 ; 52: A300 - A309
18. Nolte D. D., An R., Turek J., et al. Holographic Tissue Dynamics Spectroscopy. J. Biomed. Optics. 2011 ; 16: 087004-087013
19. Jeong K., Turek J. J., Nolte D. D.. Speckle Fluctuation Spectroscopy of Intracellular Motion in Living Tissue Using Coherence-Domain Digital Holography. J. Biomed. Optics. 2010 ; 15: 030514
20. Nolte D. D., An R., Turek J. J., et al. Tissue Dynamics Spectroscopy for Phenotypic Profiling of Drug Effects in Three-Dimensional Culture. Biomed. Opt. Express. 2012 ; 3: 2825-2841
21. Nolte D. D., An R., Turek J., et al. Tissue Dynamics Spectroscopy for Three-Dimensional Tissue-Based Drug Screening. J. Lab. Autom. 2011 ; 16: 431-442
22. Friedrich J., Ebner R., Kunz-Schughart L. A.. Experimental Anti-Tumor Therapy in 3-D: Spheroids - Old Hat or New Challenge?. Int. J. Radiat. Biol. 2007 ; 83: 849-871 (Pubitemid 350219104)
23. Nadanaciva S., Will Y. Current Protocols in Toxicology. Maines M. D., ed. 2009:
24. Davies H., Bignell G. R., Cox C., et al. Mutations of the BRAF Gene in Human Cancer. Nature. 2002 ; 417: 949-954 (Pubitemid 34716871)
25. Brose M. S., Volpe P., Feldman M., et al. BRAF and RAS mutations in Human Lung Cancer and Melanoma. Cancer Res. 2002 ; 62: 6997-7000 (Pubitemid 35424092)
26. Samowitz W. S., Sweeney C., Herrick J., et al. Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers. Cancer Res. 2005 ; 65: 6063-6070 (Pubitemid 40994390)
27. Eisen T., Ahmad T., Flaherty K. T., et al. Sorafenib in Advanced Melanoma: A Phase II Randomised Discontinuation Trial Analysis. Br. J. Cancer. 2006 ; 95: 581-586 (Pubitemid 44325897)
28. Joseph E. W., Pratilas C. A., Poulikakos P. I., et al. The RAF Inhibitor PLX4032 Inhibits ERK Signaling and Tumor Cell Proliferation in a V600E BRAF-Selective Manner. Proc. Natl. Acad. Sci. U. S. A. 2010 ; 107: 14903-14908
29. Bollag G., Hirth P., Tsai J., et al. Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-Mutant Melanoma. Nature. 2010 ; 467: 596-599
30. Hatzivassiliou G., Song K., Yen I., et al. RAF Inhibitors Prime Wild-Type RAF to Activate the MAPK Pathway and Enhance Growth. Nature. 2010 ; 464: 431-435
31. Poulikakos P. I., Zhang C., Bollag G., et al. RAF Inhibitors Transactivate RAF Dimers and ERK Signalling in Cells with Wild-Type BRAF. Nature. 2010 ; 464: 427-430
32. Hoeflich K. P., Herter S., Tien J., et al. Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAF(V600E) Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression. Cancer Res. 2009 ; 69: 3042-3051
33. Karamata B., Hassler K., Laubscher M., et al. Speckle Statistics in Optical Coherence Tomography. J Opt. Soc. Am. A Opt. Image Sci. Vis. 2005 ; 22: 593-596 (Pubitemid 40556122)
34. Tsiper M. V., Sturgis J., Avramova L. V., et al. Differential Mitochondrial Toxicity Screening and Multi-parametric Data Reduction. PloS One. in press ;:
35. Ferrante A., Rainaldi G., Indovina P., et al. Increased Cell Compaction Can Augment the Resistance of HT-29 Human Colon Adenocarcinoma Spheroids to Ionizing Radiation. Int. J. Oncol. 2006 ; 28: 111-118